Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

March 16, 2018: By Joan McKenna

Bar-Ilan University in Israel announced March 8 that it is developing an eye drop filled with synthetic nanoparticles as a non-invasive method to correct refractive errors.

Researchers previously described their work at the 2017 meeting of the European Society of Cataract and Refractive Surgeons.

The eye drops, branded Nano-Drops, work in conjunction with a laser source to apply an optical pattern to the superficial layer of the corneal epithelium to change the refractive index, or the trajectory of light passing through the cornea, according to developers. Surgeons can adjust the shape of the pattern for correction of myopia, hyperopia, or presbyopia.

The university said the laser stamping takes a few milliseconds.

Bar-Ilan said a future use might consist of patients having their vision corrected in the comfort of their own home. The school envisions patients opening an application on their smartphone to measure their vision, connecting the laser source device for stamping the optical pattern at the desired correction, and applying the Nano-Drops to activate the pattern and provide the desired correction.

The university said the technology has shown through ex-vivo experiments that it can correct nearly 3 diopters of myopia and presbyopia in pig eyes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023